A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as Monotherapy Treatment in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy.

Trial Profile

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as Monotherapy Treatment in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2017

At a glance

  • Drugs Dexmecamylamine (Primary) ; Duloxetine
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms EXPLORER
  • Most Recent Events

    • 09 May 2012 Additional lead trial investigator added as reported by Clinical Trials Registry - India.
    • 11 Apr 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 23 Nov 2011 New source identified and integrated (Clinical Trials Registry - India record, CTRI2011-10-002065).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top